ANI Pharmaceuticals Inc
NASDAQ:ANIP
ANI Pharmaceuticals Inc
Revenue
ANI Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ANI Pharmaceuticals Inc
NASDAQ:ANIP
|
Revenue
$486.8m
|
CAGR 3-Years
33%
|
CAGR 5-Years
19%
|
CAGR 10-Years
32%
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$81.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$58.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$34.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
ANI Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
ANI Pharmaceuticals Inc
Total Revenue:
486.8m
USD
|
United States:
486.3m
USD
|
Canada:
565k
USD
|
Breakdown by Segments
ANI Pharmaceuticals Inc
Total Revenue:
486.8m
USD
|
Sales Of Generic Pharmaceutical Products:
269.4m
USD
|
Sales Of Rare Disease Pharmaceutical Products:
112.1m
USD
|
Sales Of Established Brand Pharmaceutical Pro...:
105.3m
USD
|
Unapproved Products:
22.4m
USD
|
See Also
What is ANI Pharmaceuticals Inc's Revenue?
Revenue
486.8m
USD
Based on the financial report for Dec 31, 2023, ANI Pharmaceuticals Inc's Revenue amounts to 486.8m USD.
What is ANI Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
32%
Over the last year, the Revenue growth was 54%. The average annual Revenue growth rates for ANI Pharmaceuticals Inc have been 33% over the past three years , 19% over the past five years , and 32% over the past ten years .